González CJH, Treviño CEE, Cuervo LEE, Martínez López-Portillo A, Mohamed HJ

Language: Spanish
References: 29
Page: 190-199
PDF size: 491.21 Kb.

ABSTRACT

Purpose: To determine the effectiveness of the subthreshold (invisible) doubled frequency Nd:YAG (532 nm) laser in the treatment of the clinically significant diabetic macular edema.
Methods: Eighty-four eyes of 54 diabetic patients with clinical significant macular edema were prospectively treated with subthreshold (invisible) doubled frequency Nd:Yag laser photocoagulation. Follow-up was conducted for twelve months. We evaluated the evolution of the macular edema, treatment repetition, the visual acuity, the presence of scotomas and the post-laser macular complications.
Results: The reduction or elimination of the macular edema was observed in 67.9% of the eyes in the first 6 months after one or two treatment sessions and in 85.7% of the eyes with one to four treatment sessions after 12 months follow-up. Visual acuity improved in 48.8% of cases and in 34.5% it remained stable. No patient complained of scotomas after treatment and there were no laser complications.
Conclusions: Subthreshold (invisible) double frequency Nd:Yag laser photocoagulation is effective in the resolution of the clinically significant diabetic macular edema and also reduces the presence of conventional post-laser macular complications.

REFERENCES

1. Patz A, Schatz H, Berkow J, et al. Macular edema- an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 1973;77:34-42.

2. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol 1980;90:210-6.

3. Aiello LM, Rand LI, Briones JC, et al. Diabetic retinopathy in Joslin clinic patients with adult-onset diabetes. Ophthalmology 1981;88:619-23.

4. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetes retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.

5. McMeel JW, Trempe CL, Franks EB. Diabetic maculopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977;83:476-87.

6. Moss JW, Klein R, Klein BEK, et al. The incidence of vision loss in a diabetic population. Ophthalmology 1988;95:1340-8.

7. Klein R, Moss SE, Klein BEK et al. The Wisconsin epidemiologic study of diabetes retinopathy XI. The incidence of macular edema. Ophthalmology 1989;96:1501-10.

8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Research Group ETDRS Report No 1. Arch Ophthalmol 1985;103:1796-806.

9. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Research Group ETDRS Report No 2. Ophthalmology 1987;94:761-74.

10. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Research Group ETDRS Report No 4. Int Ophthalmol Clin 1987;27:265-72.

11. Blankenship GW. Diabetic macular edema and argon laser photocoagulation: a prospective randomized study. Ophthalmology 1979;86:69-75.

12. British Multicenter Study Group. Photocoagulation for diabetic maculopathy. A randomized controlled clinical trial using the xenon arc. Diabetes 1983;32:1010-6.

13. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 1986;93:939-50.

14. Olk RJ. Argon green (514 nm) versus krypton rd (647 nm) modified grid photocoagulation for diffuse diabetic macular edema. Ophthalmology 1990;97:1101-13.

15. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long term visual results. Ophthalmology 1991;98:1594-602.

16. Akduman L, Olk RJ. Laser photocoagulation of diabetic macular edema. Ophthalmic Surg Lasers 1997;28:387-408.

17. Akduman L, Olk RJ. Diode laser (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema (DDME). Ophthalmology 1997;104:1433-41.

18. McHugh JDA, Marshall J, Ffytche TJ, et al. Macular photocoagulation of human retina with diode laser: a comparative histopathological study. Lasers Light Ophthalmology 1990;3:11-28.

19. Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers 1999;30:706-14.

20. Gupta V, Gupta A, Kaur R, Narang S, Dogra MR. Efficacy of various laser wavelengths in the treatment of clinically significant macular edema in diabetics. Ophthalmic Surg Lasers 2001;32:397-405.

21. Pollack JS, Kim JE, Pulido JS, Burke JM. Tisue effects of subclinical diode laser treatment of the retina. Arch Ophthalmol 1998;116:1633-9.

22. Bonafonte S, García C. Retinopatía diabética. Harcourt Brace Publisher International, 1998.

23. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-17.

24. Clover GM. The effects of argon and krypton photocoagulation on the retina: implications for the inner and outer blood retinal barriers. In: Gitter KA, Schatz H, Yannuzzy LA, et al, editors Laser photocoagulation of retinal diseases. San Francisco: Pacific Medical Press, 1988;pp:11-18.

25. Peyman GA, Spitznas M, Straatsma BR. Peroxidase diffusion in the normal and photocoagulated retina. Invest Ophthalmol 1971;10:181-9.

26. Peyman GA, Spitznas M, Straatsma BR. Chorioretinal diffusion of peroxidase before and after photocoagulation. Invest Ophthalmol 1971;10:489-95.

27. Peyman GA, Bok D. Preoxidase diffusion in the normal and laser-coagulated primate retina. Invest Ophthalmol 1972;11:35-45.

28. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990;97:503-10; discussion 510-11.

29. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetes macular edema. EDTRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997;115:873-7.